On Friday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) opened higher 8.41% from the last session, before settling in for the closing price of $26.29. Price fluctuations for NAMS have ranged from $14.06 to $27.35 over the past 52 weeks.
Company’s average yearly earnings per share was noted 46.56% at the time writing. With a float of $73.28 million, this company’s outstanding shares have now reached $112.51 million.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of NewAmsterdam Pharma Company NV is 34.94%, while institutional ownership is 61.59%. The most recent insider transaction that took place on Sep 15 ’25, was worth 15,639. In this transaction Director of this company bought 660 shares at a rate of $23.70, taking the stock ownership to the 3,028,524 shares. Before that another transaction happened on Sep 09 ’25, when Company’s Chief Accounting Officer sold 150,000 for $25.83, making the entire transaction worth $3,874,017. This insider now owns 15,000 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.16 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.45) by 0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year. According to the Wall Street analysts, stocks earnings will be around 46.56% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Check out the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). In the past quarter, the stock posted a quick ratio of 21.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Compared to the last year’s volume of 0.89 million, its volume of 0.62 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 86.60%.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 99.07%, which indicates a significant increase from 98.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.46 in the past 14 days, which was higher than the 1.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.61, while its 200-day Moving Average is $21.73. Nevertheless, the first resistance level for the watch stands at $29.41 in the near term. At $30.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.02. If the price goes on to break the first support level at $26.80, it is likely to go to the next support level at $25.09. Should the price break the second support level, the third support level stands at $24.19.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are currently 112,628K shares outstanding in the company with a market cap of 3.21 billion. Presently, the company’s annual sales total 45,560 K according to its annual income of -241,600 K. Last quarter, the company’s sales amounted to 19,150 K and its income totaled -17,360 K.
